Diaceutics (LON:DXRX) Reaches New 1-Year High – Still a Buy?

Diaceutics PLC (LON:DXRX) shares hit a new 52-week high during mid-day trading on Monday. The stock traded as high as GBX 210 and last traded at GBX 206.50, with a volume of 227,890 shares trading hands. The stock had previously closed at GBX 203.52.

Analyst Ratings Changes

Separately, Canaccord Genuity Group restated a “buy” rating and set a GBX 215 target price on shares of Diaceutics in a report on Tuesday, September 22nd. Two equities research analysts have rated the stock with a Buy rating. According to data from MarketBeat, the stock presently has an average rating of “Buy” and a consensus price target of GBX 215.

Diaceutics Trading Down 2.0%

The business’s fifty day simple moving average is GBX 169.47 and its 200 day simple moving average is GBX 158.14. The company has a current ratio of 2.55, a quick ratio of 9.92 and a debt-to-equity ratio of 5.40. The stock has a market cap of £170.21 million, a P/E ratio of -626.56 and a beta of 0.88.

Diaceutics (LON:DXRX) last posted its quarterly earnings data on Tuesday, September 22nd. The company reported GBX (3.27) earnings per share for the quarter. Diaceutics had a negative net margin of 0.66% and a negative return on equity of 0.68%. As a group, analysts expect that Diaceutics PLC will post 1.01 EPS for the current year.

Diaceutics Company Profile

At Diaceutics we believe that every patient should get the opportunity to receive the right test and the right therapy to positively impact their disease outcome. We provide the world’s leading pharma and biotech companies with an end-to-end commercialisation solution for precision medicines through data analytics, scientific and advisory services enabled by our platform DXRX – The Diagnostics Network®.